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RESUMEN
Se ha sintetizado  pirimidotiazepina y varios de sus deri-
vados partiendo del tratamiento de 6-cloro-1-metiluracilo 
con glicolato de etilo seguido de reacción con hidrato de 
hidrazina a reflujo, lo cual conduce a la ciclacion con los 
aldehídos aromátios apropiados, o mediante tratamiento 
con  2-aminotiofenol seguido de reflujo con los aldehídos 
aromáticos adecuados respectivamente. La estructura de 
los compuestos sintetizados se confirma mediante datos 
de IR, 1H RMN, espectrometría de masas y análisis ele-
mental. Además, se investigó la unión y fragmentación del 
ácido nucleico ADN de los nuevos derivados.
Palabras clave: 6-Chloro-1-metiluracilo, pirimidotiazepi-
na,  pirimidobenzotiazepina.
SUMMARY
Several pyrimidothiazepine and pyrimidobenzothiazepine 
were synthesized starting from 6-chloro-1-methyluracil 
by the treatment with ethyl thioglycolate followed by the 
reaction with hydrazine hydrate which cyclized through 
refluxing with appropriate aromatic aldehydes or by the 
treatment with 2-aminothiophenol followed by refluxing 
with appropriate aromatic aldehydes respectively. The 
structure of newly synthesized compounds was confirmed 
by IR, 1H NMR, mass spectral data and elemental analy-
sis. Further the novel derivatives were investigated for their 
binding and fragmentation of the nucleic acid DNA. 
Keywords:  6-Chloro-1-methyluracil, pyrimidothiazepine 
and pyrimidobenzothiazepine.
RESUM
S’ha sintetitzat  pirimidotiazepina i varis dels seus derivats 
partint del tractament de 6-clor-1-metiluracil amb glicolat 
d’etil seguit de reacció amb hidrat d’hidrazina a reflux, la 
qual cosa condueix a la ciclació amb els aldehids aromà-
tics apropiats, o mitjançant tractament amb  2-aminotiofe-
nol seguit de reflux amb els aldehids aromàtics adequats 
respectivament. L’estructura dels compostos sintetitzats 
es confirma mitjançant dades d’IR, 1H-RMN, espectrome-
tria de masses i anàlisi elemental. A més, es va investigar 
la unió i fragmentació de l’àcid nucleic ADN dels nous de-
rivats.
Paraules clau: 6-Chloro-1-metiluracil, pirimidotiazepina, 
pirimidobenzotiazepina.
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INTRODUCTION
Great efforts have been directed towards the discovery 
of chemotherapeutic agents belong chemically to the 
nucleoside and nonnucleoside uracil derivatives. These 
compounds have both antimetabolites1-4 such as the non-
nucleoside derivatives 1-[(2-hydroxyethoxy) methyl]-
6-(phenylsulfanyl)thymine (HEPT, 163) and its derivatives 
1625-7, methotrexate8 and the antiviral activity especially 
against human immunodeficiency virus (HIV)9-13, also the 
etiological agent of acquired immunodeficiency syndrome 
(AIDS)14-16 like the non-nucleoside derivatives of acyclovir 
(159)17, famciclovir (160), ganciclovir  (161)18, acridines, di-
hydroxyacridone19 and nevirapine.20-22 Uracil nucleo- sides 
have been studied as antimetabolites because they fol-
low similar metabolic pathways as do the corresponding 
natural pyrimidines.  This leads to inhibition of certain viral 
enzymes through their highly potent reverse transcriptase 
inhibitors by being incorporated into the viral DNA chain, 
resulting in obligatory viral DNA chain termination.23-25
In the view of the facts mentioned above and as part of 
our initial efforts to discover potentially active new agents, 
we have synthesized some new pyrimidothiazepine and 
pyrimidobenzothiazepine which hopping to have antime-
tabolite and/or antiviral activity.
MATERIALS AND METHODS
Chemistry
All melting points were determined with an Electrother- 
mal Mel.-Temp. II apparatus and were uncorrected.   El- 
emental analyses were performed at the Micro Analytical 
Unit, Chemistry Department, Mansoura University, Egypt. 
The infrared (IR) spectra were recorded using potassium 
bromide disc technique on Nikolet IR 200 FT IR at Phar-
maceutical Analytical Unit, Faculty of Pharmacy, Al-Azhar 
University.  The proton nuclear magnetic resonance (1H- 
NMR) spectra were recorded on Varian Gemini 300 MHz 
Spectrometer using DMSO-d6 as a solvent and tetrameth-
ylsilane (TMS) as an internal standard (Chemical shift in 
δ, ppm), Faculty of Science, Chemistry Department,Cairo 
University, Egypt.  Mass spectra were recorded on DI-50 
unit of Shimadzu GC/MS-QP 5050A at the Regional Cen-
ter for Mycology and Biotechnology at Al-Azhar University, 
Egypt. All reactions were monitored by TLC using silica gel 
(Merck 60 F254). The used solvent system was chloroform: 
methanol (9:1) & ethyl acetate: toluene (1:1).
6-[((Hydrazinecarbonyl)methyl)sulfanyl]-1-methyluracil
(IV)
A mixture of 6-[((ethoxycarbonyl)methyl)sulfanyl]-1-meth- 
yluracil (III) (0.29 g, 1.2 mmol) and hydrazine hydrate (0.12 
g, 2.4 mmol) in ethanol (10 ml) was stirred at room tem- 
perature for 15 minutes.  The formed precipitate was col- 
lected by filtration, washed with ethanol and crystallized 
from DMF into colourless crystals.
Yield: (84%), m.p. 258-260 °C. IR: 3260, 3157 (NH2 & NH), 
3029 (CH- arom.), 2910 (CH- aliph.), 1694 (br, C = O), 1560 
(C = C). Anal. Calcd for C7H10N4O3S (230.24): Calcd. C, 
36.52, H, 4.38, N, 24.33, Found C, 36.90, H, 4.17, N, 24.79
6-[(Arylmethylidene)amino]-5-hydroxy-1-methyl-5,6- 
dihydropyrimido[5,4-f][1,4]thiazepine-2,4,7(1H,3H,8H)- 
triones (Va-f)
A    mixture    of    6-[((hydrazinecarbonyl)methyl)sulfanyl]-
1-methyluracil (IV) (0.3 g, 1.3 mmol) and the appropriate
aromatic aldehydes (1.3 mmol) in dry DMF (4 ml) was heat- 
ed under reflux for 2 hours.  After cooling, ethanol (7.0 ml) 
was added; the separated product was filtered, washed 
with ether and crystallized from DMF/ethanol (1:1) to af- 
ford V.
6-[(benzylidene)amino]-5-hydroxy-1-methyl-5,6- 
dihydropyrimido[5,4-f][1,4]thiazepine-2,4,7(1H,3H,8H)- 
triones Va
Yield: 80%, m.p. 252-254°C. IR: 3431 (OH), 3141 (NH),
3067 (CH arom.), 2989, 2863 (CH aliph.), 1665 (C = O), 
1554 (C = C), 690, 759 (monosubstituted phenyl). Anal. 
Calcd for C15H14N4O4S (346.36): Calcd. C, 52.02, H, 4.07, 
N, 16.18, Found C, 51.99, H, 4.09, N, 16.13.
6-[(4-chlorobenzylidene)amino]-5-hydroxy-1-meth- 
yl-5,6-dihydropyrimido[5,4-f][1,4]thiazepine-2,4,7-
(1H,3H,8H)-triones Vb
Yield: 86%, m.p. 285-287°C. IR: 3222 (OH), 3149 (NH),
3012 (CH arom.), 2833 (CH aliph.), 1669 (br, C = O), 1551 
(C = C), 829 (p-substituted  phenyl).1H-NMR (DMSO-d6) 
δ ppm:  11.83 (s, 1H, NH, exchangeable), 11.22, 11.24 (2 
unequal s, 1H, OH, exchangeable), 8.21, 8.03 (2 unequal 
s, 1H, CH=N), 7.77-7.72 (d, 2H, arom.), 7.52-7.49 (d, 2H, 
arom.), 5.52-5.48 (2 unequal s, 1H, CH-5), 4.39, 3.98 (2 
unequal s, 2H, CH2-8), 3.34 (s, 3H, NCH3). MS m/z (%):
380 (M, 0.04), 366 (0.05), 278 (14), 269 (0.47), 243 (0.75),
214 (28), 199 (100), 158(35). Anal. Calcd for C15H13ClN4O4S 
(380.80): Calcd. C, 47.31, H, 3.44, N, 14.71, Found C, 
47.41, H, 3.46, N, 14.43.
6-[(4-Fluorobenzylidene)amino]-5-hydroxy-1-meth- 
yl-5,6-dihydropyrimido[5,4-f][1,4]thiazepine-2,4,7(1H,
3H, 8H)-triones Vc
Yield: 81%, m.p. 254-256°C. IR: 3426 (OH), 3144 (NH),
3023 (CH arom.), 2922, 2849 (CH aliph.), 1708, 1672, 1650 
(C = O), 1548 (C = C), 820 (p-substituted phenyl). Anal. 
Calcd for C15H13N4O4S (364.35): Calcd. C, 49.45, H, 3.60, 
N, 15.38, Found C, 49.56, H, 3.73, N, 15.51.
6-[(4-Bromobenzylidene)amino]-5-hydroxy-1-meth-yl-
5,6-dihydropyrimido[5,4-f][1,4]thiazepine-2,4,7 (1H,
3H, 8H)-triones Vd
Yield: 79%, m.p. 259-260 °C. IR:  3449 (OH), 3137 (NH), 
3067 (CH arom.), 2858 (CH aliph.), 1715, 1668 (C = O), 
1553 (C = C), 838 (p-substituted phenyl). 1H-NMR (DMSO- 
d6) δ ppm:  11.83 (s, 1H, NH), 11.22, 11.24 (2 unequal s, 
1H, OH), 8.20, 8.02 (2 unequal s, 1H, CH=N), 7.71-7.63 (m, 
4H, arom.), 5.52-5.48 (2 unequal s, 1H, CH-5), 4.39, 3.98 (2 
unequal s, 2H, CH2-8), 3.34 (s, 3H, NCH3). Anal. Calcd for 
C15H13BrN4O4S (425.25): Calcd. C, 42.37, H, 3.08, N, 13.17, 
Found C, 42.39, H, 3.10, N, 13.08.
6-[(4-Hydr oxybenzylidene)amino]-5-hydr oxy- 
1-methyl-5,6-dihydropyrimido[5,4-f][1,4]thiaze-
pine-2,4, 7(1H,3H,8H)-triones Ve
Yield: 67%, m.p. 298-300 °C. IR: 3238 (OH), 3163 (NH), 
3049 (CH arom.), 2997, 2852 (CH aliph.), 1719, 1657 (C = 
O), 1553 (C = C), 833 (p-substituted phenyl). Anal. Calcd 
for C15H14N4O5S (362.36): Calcd. C, 49.72, H, 3.89, N, 
15.46, Found C, 49.42, H, 3.60, N, 15.27.
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6-[(4-nitrobenzylidene)amino]-5-hydroxy-1-meth- 
yl-5,6-dihydropyrimido[5,4-f][1,4] thiazepine-2,4,7(1H,
3H, 8H)-triones Vf
Yield: 62%, m.p. 295-296 °C. IR: 3402 (OH), 3129 (NH),
3005 (CH arom.), 2841 (CH aliph.), 1714, 1682, 1665 (C 
= O), 1565 (C = C), 1518, 1348 (NO2), 845 (p- substituted 
phenyl). Anal. Calcd for C15H13N5O6S (391.35): Calcd. C, 
46.03, H, 3.35, N, 17.89, Found C, 46.40, H, 3.44, N, 17.72.
6-[(2-Aminophenyl)sulfanyl]-1-methyluracil (VI)
To a solution of 6-chloro-1-methyluracil (II) (1.0 g, 6.23 
mmol) in hot chloroform (10 ml), few drops of TEA (0.4 ml) 
and 2-aminothiophenol (0.8 g, 6.23 mmol) were added. 
After cooling, the reaction mixture was stirred at room 
temperature for 30 minutes.  The formed precipitate was 
filtered, washed with ethanol and crystallized from DMF/ 
ethanol (2:1) into colourless crystals.
Yield: (81%), m.p.: 270-272 °C.  IR:    3370, 3297 (NH2 & 
NH), 3060 (CH arom.), 2994, 2856 (CH aliph.), 1700, 1673 
(2 C = O), 1564 (C = C), 760 (o-substituted phenyl). Anal. 
Calcd for C11H11N3O2S (249.28): Calcd. C, 53.00, H, 4.45, 
N, 16.86,   Found: C, 53.00, H, 4.53, N, 16.38.
5-Aryl-1-methyl-5,6-dihydropyrimido[4,5-b][1,5]benzo- 
thiazepine-2,4(1H,3H)-diones (VIIa-d)
A mixture of 6-[(2-aminophenyl)sulfanyl]-1-methyluracil 
(VI) (0.3 g, 1.2 mmol) and the appropriate aromatic alde-
hyde (1.2 mmol) in acetic acid (3 ml) was heated under re-
flux for 8 hours. After cooling, ethanol (8.0 ml) was added; 
the formed precipitate was filtered, washed with ethanol 
and crystallized from DMF/ethanol (1:1) to afford VIIa-d.
5-(4-Chloro)-1-methyl-5,6-dihydropyrimido[4,5-b][1,5]
benzothiazepine-2,4(1H,3H)-diones VIIa
Yield: 78%, m.p.:  190-192 °C.    IR:   3265, 3162 (NH),
3100(CH arom.), 2985 (CH aliph.), 1716 (br, 2 C = O), 1557 
(C = C), 820 (p-substituted phenyl), 754 (o-substituted 
phenyl).  1H-NMR (DMSO-d6) δ ppm:  11.04 (s, 1H, NH), 
8.26 (s, 1H, NH), 8.11-8.09 (d, 1H, arom.), 8.01-7.99 (d,
1H, arom.), 7.60-7.25 (m, 7H, arom. CH-5), 3.47 (s, 3H, 
NCH3). MS m/z (%): 373 (M+2 , 12), 371 (M , 44), 339 (23),
313 (54), 297 (12), 270 (92), 260 (64), 235 (74), 203 (19),
58 (100). Anal. Calcd for C18H14ClN3O2S (371.84): Calcd. 
C, 58.14, H, 3.79, N, 11.30, Found C, 58.68, H, 4.13, N, 
11.02.
5-(4-Bromo)-1-methyl-5,6-dihydropyrimido[4,5-b][1,5]
benzothiazepine-2,4(1H,3H)-diones VIIb
Yield: 71%, m.p.: 250-252 °C.  IR: 3260, 3157 (NH), 3086 
(CH arom.), 2959 (CH aliph.), 1715, 1674 (2 C = O), 1557 (C
= C), 818 (p-substituted phenyl), 755 (o-substituted phe- 
nyl). Anal. Calcd for C18H14BrN3O2S (416.84): Calcd. C, 
51.93, H, 3.39, N, 10.09, Found C, 51.70, H, 3.40, N, 10.51.
5-(4-Fluoro)-1-methyl-5,6-dihydropyrimido[4,5-b][1,5]
benzothiazepine-2,4(1H,3H)-diones VIIc
Yield: 82%, m.p.: 293-295 °C.   IR: 3240 (NH), 3117 (CH 
arom.), 2986, 2819 (CH aliph.), 1704, 1637 (2 C = O), 1564 
(C = C), 827 (p-substituted phenyl), 754 (o-substituted 
phenyl). Anal. Calcd for C18H14FN3O2S (355.38): Calcd. C, 
60.83, H, 3.97, N, 11.82, Found C, 60.45, H, 3.81, N, 11.79.
5-(4-nitro)-1-methyl-5,6-dihydropyrimido[4,5-b][1,5]
benzothiazepine-2,4(1H,3H)-diones VIId
Yield: 59%, m.p.: 218-220 °C.   IR: 3242 (NH), 3116 (CH 
arom.), 2989, 2849 (CH aliph.), 1703, 1636 (2 C = O), 1564 
(C = C), 1525, 1340 (NO2), 821 (p-substituted phenyl), 754
(o-substituted phenyl). Anal. Calcd for C18H14N4O4S 
(382.39): Calcd. C, 56.54, H, 3.69, N, 14.65, Found C, 
56.50, H, 3.91, N, 15.04.
BIOLOGICAL EVALUATION
Nucleic acids preparation
For extraction of genomic DNA, yeast cells were washed 
with cold phosphate borate sodium chloride (PBS) buffer 
and lysed in a buffer containing 50 mM Tris-HCl (pH 8.0), 1 
mM EDTA, 0.2% Triton X-100 for 20 min at 4 ºC.  After cen-
trifugation at 14,000 rpm for 15 min, the supernatant was 
treated with proteinase K (0.5 mg/ml) and 1% SDS for 1 h
at 50 ºC.  DNA was extracted twice with buffered phe- 
nol/chloroform and precipitated with 140 mM NaCl and 2 
volumes of ethanol at - 20 ºC overnight.  DNA precipitates 
were washed twice with 70% ethanol, air-dried and dis- 
solved in TE buffer, and treated for 1 h at 37 ºC with RNase 
A according to reported method.26 Finally, DNA prepara-
tions were electrophoresed in 1% agarose gels.
Agarose gel preparation and visualization of DNA
1% Agarose gel was prepared by adding 1gm ultra aga-
rose to 100 ml Tris-Acetate-EDTA (TAE) buffer and heated 
in a microwave oven then cooled to ~60°C before pouring 
in gel tray.
Examination of the gel was carried out using ultraviolet illu- 
minated box.  Ethidium bromide (0.1 mg/ml) solution was 
used to stain the nucleic acid (DNA bands) in the gel as 
it intercalates between DNA bases and give florescence. 
The gel was photographed using polarized camera.
Nucleic acid affinity, binding and fragmentation assay 
the test compounds were dissolved in DMSO at 20 µg/µl 
concen-trations, mixed with 2 µg /µl DNA and incubated at 
room temperature for 2 hrs. The mixtures were mixed with 
the gel loading buffer and then electrophoresed in the aga-
rose gel (1% w/v) at 80 V for 1.5 hrs. As positive control for 
affinity, binding and fragmentation, methotrexate (20 µg/ 
µl) was mixed with DNA and as negative control DMSO 
was mixed with equal amount of DNA. After running, aga-
rose gel was stained with ethidium bromide and visualized 
using polarized camera.
RESULTS AND DISCUSSION
Chemistry
6-Chlorouracil27 was prepared by the alkaline hydrolysis 
of  2,4,6-trichloropyrimidine.28,29    This compound  was 
methylated with methyl iodide in the presence of potas-
sium carbonate applying a reported procedure.30 The di-
rect reaction of 6-chloro-1-methyluracil (II) with ethyl thio- 
glycolate in the presence of triethylamine (TEA) produce 
the target ester III in a good yield.31 In the course of this 
investigation, the ester III was allowed to react with hydra- 
zine hydrate at room temperature to yield the acid hydra- 
zide IV which on reaction with certain aromatic aldehydes 
namely,  benzaldehyde,  4-hydroxy-,   4-nitro-,   4-chloro-,
4-bromo-, and 4-fluorobenzaldehydes in dry DMF, gave 
rise to the corresponding pyrimidothiazepines Va-f and 
no hydrazones could be isolated as shown in (scheme 
1). Literature32,33 survey directed the attention to explain 
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that the reaction pathway for the formation of compounds 
Va-f may be through formylation of the pyrimidine ring IV 
at the active 5-position.   At the same time, condensa-
tion between the acid hydrazide and the used aldehyde is 
achieved.  Simultaneous cyclization via intramolecular ad-
dition of the hydrazone NH to the formyl group is affected 
to bring about target com- pounds Va-f. 1H-NMR (DMSO-
d6) for Vb (R = Cl) showed a singlet exchangeable signal at 
δ = 11.83 ppm indicating NH at 3 position, two unequal ex-
changeable singlets at δ = 11.22 & 11.24 ppm correspond-
ing to OH at 5-position and two unequal singlets corre-
sponding to one H at 5-position at δ = 5.52 & 5.48 ppm 
indicating the asymmetric center (nonequal mixture of R 
& S isomers).  Also, the methylidene group CH appeared 
as 2 unequal singlets at δ = 8.21 & 8.03 ppm indicating 
two isomeric forms (Z & E). Similarly, CH2 at 8-position 
appeared as two unequal signals at δ = 4.39 & 3.98 ppm. 
Compound Vd showed the same observations.
On the other hand, a mixture of 6-chloro-1-methyluracil (II) 
and 2-aminothiophenol was allowed to react at room tem-
perature in the presence of TEA produced the thioether VI. 
Condensation of VI with aromatic aldehydes in acid me- 
dium resulted in intramolecular cyclisation of the formed 
arylidene derivatives to furnish pyrimidobenzothiazepines 
VIIa-d as shown in (scheme 1). 1H-NMR (DMSO-d6) for 
VIIa (R= Cl) showed two broad singlets at δ = 11.04 & 8.26 
ppm characteristic for two NH groups, two doublets at δ =
8.11 & 8.01 ppm (2H) at 3 & 5 positions of 4-chlorophenyl 
group, a multiplet at δ = 7.60-7.25 ppm characteristic for 7 
protons (6 aromatic and one at 5-position), and a singlet at 
δ = 3.47 ppm characteristic for NCH3. The appearance of 
signals of two protons at 3 & 5 position of the phenyl group 
as two separate doublets indicated that the compound is 
present in two isomeric forms, R & S. 
scheme 1
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BIOLOGICAL EVALUATION
The newly synthesized compounds were subjected to nu- 
cleic acid binding assay using agarose gel electrophoresis 
method.
Nucleic acids binding assay
Different synthetic drugs induced DNA damage was evalu- 
ated by measuring the level of genomic DNA fragmenta- 
tion and detecting DNA ladders on agarose gel electro- 
phoresis (Fig. 1). Compared to the vehicle control group 
(lane 2 negative control and 3 positive control), there was 
no significant change in genomic DNA fragmentation in 
some treated groups. There were major differences in the 
response of extracted DNA (from Lanes 4-14 in figure 1). 
It is possible that drugs exerted its effect solely by indirect 
mechanisms. This contrast may have been due to differ- 
ent enzyme(s) being with differing susceptibilities to drugs.
Figure 1. Gel electrophoresis 1%w/v agarose of un-
treated and treated genomic DNA. Lane M: Molecular 
weight marker (left side); Lane 1: Untreated nucleic acid;
Lane 2: DMSO treated nucleic acid (negative control);
Lane 3: Methotrexate treated nucleic acid (positive control); 
Lanes 4-14: Compounds (VIIa-d, IV, Va-f) treated nucleic acid.
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